Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ezogabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 known ✓ | O43526 | 8/20 | 1.00 |
| ▸ | KCNQ3 known ✓ | O43525 | 6/20 | 1.00 |
| ▸ | KCNQ4 known ✓ | P56696 | 6/20 | 1.00 |
| ▸ | KCNQ5 known ✓ | Q9NR82 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ezogabine SCHEMBL4054750 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL29359156 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL15357224 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL154715 | 0.99 | KCNQ2 (0.98) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL155918 | 0.99 | KCNQ2 (0.98) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL15539530 | 0.97 | KCNQ2 (0.94) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| SCHEMBL3102203 | 0.93 | KCNQ2 (0.87) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| SCHEMBL30824720 | 0.93 | KCNQ2 (0.87) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL28471969 | 0.93 | KCNQ2 (0.86) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| SCHEMBL29754400 | 0.91 | KCNQ2 (0.83) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4168 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026099781-A1 | METHOD | SANIA TX LTD (GB) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099804-A2 | METHOD | SANIA TX LTD (GB) | 2026-05-15 | — | — | WO | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| EP-4709865-A1 | METHOD | Sania TX Ltd (GB) | 2026-03-18 | — | — | EP | claimed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4646205-A2 | COMBINATION THERAPIES FOR TREATMENT OF HEARING DISORDERS | Gateway Biotechnology, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | claimed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | claimed |
| US-6472165-B1 | SELECTIVE MODULATORY RETIGABINE BINDING POTASSIUM CHANNEL RECEPTOR SITE CONTAINING SUBUNITS KCNQ2 AND KCNQ3 | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2002-10-29 | — | — | US | claimed |
| WO-2002080898-A2 | METHODS FOR TREATING HYPERACTIVE GASTRIC MOTILITY | WYETH (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020111379-A1 | Methods of treating anxiety disorders | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-15 | — | — | US | claimed |
| WO-2002049628-A2 | METHODS OF TREATING ANXIETY DISORDERS | WYETH (US) | 2002-06-27 | — | — | WO | claimed |
| EP-1207863-A2 | NEW USES FOR POTASSIUM CHANNEL OPENERS, SUCH AS THE TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2002-05-29 | — | — | EP | claimed |
| WO-2002032419-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2002-04-25 | — | — | WO | claimed |
| US-6348486-B1 | TREATMENT OF INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-19 | — | — | US | claimed |
| US-20020015730-A1 | Pharmaceutical formulations and method for making | AWD.PHARMA GMBH & CO. KG (DE) | 2002-02-07 | — | — | US | claimed |
| WO-2001001970-A2 | NEW USES POTASSIUM CHANNEL OPENERS, SUCH AS THE TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2001-01-11 | — | — | WO | claimed |
| US-5384330-A | Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1995-01-24 | — | — | US | claimed |